A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas.

Trial Profile

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Cancer; Neurofibromatoses
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.(NCT00652990).
    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.(NCT00652990).
    • 10 May 2012 Actual patient number is 18 according to ClinicalTrials.gov.(NCT00652990).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top